ScripChina’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,
Pink SheetKite Pharma, Inc. ’s CAR-T therapy Tecartus will remain an outlier among its peers when new safety labeling on secondary malignancy is in place, but will be much less of one after a quick change by th
Pink SheetAny questions about updating CAR-T labels to include the risk of secondary malignancy have been answered by the US Food and Drug Administration, although sponsors still are not certain the products ca